These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease. Abu El-Asrar AM; Hemachandran S; Al-Mezaine HS; Kangave D; Al-Muammar AM Acta Ophthalmol; 2012 Dec; 90(8):e603-8. PubMed ID: 22971163 [TBL] [Abstract][Full Text] [Related]
29. The prognostic value of angiography in Vogt-Koyanagi-Harada disease. Chee SP; Jap A; Cheung CM Am J Ophthalmol; 2010 Dec; 150(6):888-93. PubMed ID: 20933219 [TBL] [Abstract][Full Text] [Related]
30. Indocyanine green angiography guided management of vogt-koyanagi-harada disease. Bouchenaki N; Herbort CP J Ophthalmic Vis Res; 2011 Oct; 6(4):241-8. PubMed ID: 22454746 [TBL] [Abstract][Full Text] [Related]
31. [Clinical manifestations and diagnosis of Vogt-Koyanagi-Harada syndrome]. Yang P; Wang H; Zhou H; Huang X; Zhong H; Chen L; Zhong H; Fu T Zhonghua Yan Ke Za Zhi; 2002 Dec; 38(12):736-9. PubMed ID: 12654224 [TBL] [Abstract][Full Text] [Related]
32. Pseudo-inflammatory manifestations of choroidal lymphoma resembling Vogt-Koyanagi-Harada disease: case report based on multimodal imaging. Fukutsu K; Namba K; Iwata D; Mizuuchi K; Kase S; Suzuki K; Shimizu H; Shibata Y; Yamawaki F; Onozawa M; Ishida S BMC Ophthalmol; 2020 Mar; 20(1):94. PubMed ID: 32156266 [TBL] [Abstract][Full Text] [Related]
33. Vogt-Koyanagi-Harada Disease Managed With Immunomodulatory Therapy Within 3 Months of Disease Onset. Ei Ei Lin Oo ; Chee SP; Wong KKY; Hla Myint Htoon Am J Ophthalmol; 2020 Dec; 220():37-44. PubMed ID: 32738228 [TBL] [Abstract][Full Text] [Related]
34. Retinal vessel oxygen saturation is affected in uveitis associated with Vogt-Koyanagi-Harada disease. Abu El-Asrar AM; AlBloushi AF; Gikandi PW; Hardarson SH; Stefánsson E Br J Ophthalmol; 2019 Dec; 103(12):1695-1699. PubMed ID: 30798260 [TBL] [Abstract][Full Text] [Related]
35. The effect on choroidal changes of the route of systemic corticosteroids in acute Vogt-Koyanagi-Harada disease. Park UC; Cho IH; Lee EK; Yu HG Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1203-1211. PubMed ID: 28382438 [TBL] [Abstract][Full Text] [Related]
36. Retinal pigment epithelial changes in chronic Vogt-Koyanagi-Harada disease: fundus autofluorescence and spectral domain-optical coherence tomography findings. Vasconcelos-Santos DV; Sohn EH; Sadda S; Rao NA Retina; 2010 Jan; 30(1):33-41. PubMed ID: 20010321 [TBL] [Abstract][Full Text] [Related]
37. Delayed-onset unilateral Vogt-Koyanagi-Harada syndrome: a multimodal imaging appraisal. Verma S; Thakur H; Azad SV; Kumar V BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33568408 [TBL] [Abstract][Full Text] [Related]
38. Reappraisal of the management of Vogt-Koyanagi-Harada disease: sunset glow fundus is no more a fatality. Herbort CP; Abu El Asrar AM; Yamamoto JH; Pavésio CE; Gupta V; Khairallah M; Tugal-Tutkun I; Soheilian M; Takeuchi M; Papadia M Int Ophthalmol; 2017 Dec; 37(6):1383-1395. PubMed ID: 27844182 [TBL] [Abstract][Full Text] [Related]
39. Assessment of measurement methods of posterior inflammation in stromal choroiditis: the value of quantitative outcome measures versus the presently qualitatively based paradigm. Gillmann K; El Ameen A; Massy R; Fabro F; Gasc A; Herbort CP Int Ophthalmol; 2019 Jul; 39(7):1567-1574. PubMed ID: 29946830 [TBL] [Abstract][Full Text] [Related]
40. Choroidal bulging in patients with Vogt-Koyanagi-Harada disease in the non-acute uveitic stage. Sakata VM; da Silva FT; Hirata CE; Takahashi WY; Costa RA; Yamamoto JH J Ophthalmic Inflamm Infect; 2014 Feb; 4(1):6. PubMed ID: 24548697 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]